Daniel Lysák

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Hagop M. Kantarjian, Xavier Thomas, Anna Dmoszyńska et al. · Journal of Clinical Oncology · 2012 · 1.2K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Paolo Ghia, Andrzej Pluta, Daniel Lysák et al. · Journal of Clinical Oncology · 2020 · 362 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results

Paolo Ghia, Andrzej Pluta, Małgorzata Wach et al. · HemaSphere · 2022 · 103 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia

Jennifer R. Brown, John F. Seymour, Wojciech Jurczak et al. · New England Journal of Medicine · 2025 · 103 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +13

Factors affecting PBSC mobilization and collection in healthy donors

Daniel Lysák, Vladimír Koza, Pavel Jindra · Transfusion and Apheresis Science · 2005 · 57 citations

Public Affairs, Surgery, Transfusion Medicine +9